Food and Drug Administration (FDA) will restrict glucagon-like peptide-1 (GLP-1) active pharmaceutical ingredients (APIs) expected to be used in non-FDA-approved compounded products. In fall 2025, the agency sent warning letters to companies falsely promoting that their compounded non-FDA-approved products are generic versions of FDA-approved products. FDA intends to take further action to address misleading advertisements. Furthermore, FDA warns that entities involved in producing, distributing, or marketing unapproved compounded GLP-1 products and that do not address violations from the agency will face legal actions. More information is available in a statement from FDA.